Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04375033
PHASE4

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

Sponsor: VA Office of Research and Development

View on ClinicalTrials.gov

Summary

VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 4-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.

Official title: CSP #2014 - Comparative Effectiveness of Two Formulations of Buprenorphine for Treating Opioid Use Disorder in Veterans (VA-BRAVE)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

952

Start Date

2020-11-03

Completion Date

2029-05-31

Last Updated

2026-01-12

Healthy Volunteers

No

Interventions

DRUG

Sublingual buprenorphine with naloxone

The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.

DRUG

Injectable subcutaneous buprenorphine

Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously at each 28-day visit through Week 48.

Locations (25)

Tuscaloosa VA Medical Center, Tuscaloosa, AL

Tuscaloosa, Alabama, United States

Phoenix VA Health Care System, Phoenix, AZ

Phoenix, Arizona, United States

VA Long Beach Healthcare System, Long Beach, CA

Long Beach, California, United States

VA Palo Alto Health Care System, Palo Alto, CA

Palo Alto, California, United States

San Francisco VA Medical Center, San Francisco, CA

San Francisco, California, United States

CERC (VISN1, West Haven, CT)

West Haven, Connecticut, United States

VA Connecticut Healthcare System West Haven Campus, West Haven, CT

West Haven, Connecticut, United States

Wilmington VA Medical Center, Wilmington, DE

Wilmington, Delaware, United States

Bay Pines VA Healthcare System, Pay Pines, FL

Bay Pines, Florida, United States

North Florida/South Georgia Veterans Health System, Gainesville, FL

Gainesville, Florida, United States

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Boston, Massachusetts, United States

Minneapolis VA Health Care System, Minneapolis, MN

Minneapolis, Minnesota, United States

Louis Stokes VA Medical Center, Cleveland, OH

Cleveland, Ohio, United States

Dayton VA Medical Center, Dayton, OH

Dayton, Ohio, United States

Philadelphia MultiService Center, Philadelphia, PA

Philadelphia, Pennsylvania, United States

VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Pittsburgh, Pennsylvania, United States

Providence VA Medical Center, Providence, RI

Providence, Rhode Island, United States

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

Dallas, Texas, United States

VA Salt Lake City Health Care System, Salt Lake City, UT

Salt Lake City, Utah, United States

White River Junction VA Medical Center, White River Junction, VT

White River Junction, Vermont, United States

Hampton VA Medical Center, Hampton, VA

Hampton, Virginia, United States

Salem VA Medical Center, Salem, VA

Salem, Virginia, United States

VA Puget Sound Health Care System Seattle Division, Seattle, WA

Seattle, Washington, United States

Huntington VA Medical Center, Huntington, WV

Huntington, West Virginia, United States

Clement J. Zablocki VA Medical Center, Milwaukee, WI

Milwaukee, Wisconsin, United States